Efinaconazole-d4

• CAT Number: I026733
• Molecular Formula: C18H18D4F2N4O
• Molecular Weight: 352.4222
• Purity: 98%
• Synonyms: Efinaconazole-d4; Efinaconazole d4
• Solubility: To be determined
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1-yl-2,2,6,6-d4)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol
• InChI: InChI=1S/C18H22F2N4O/c1-13-5-7-23(8-6-13)14(2)18(25,10-24-12-21-11-22-24)16-4-3-15(19)9-17(16)20/h3-4,9,11-12,14,25H,1,5-8,10H2,2H3/t14-,18-/m1/s1/i7D2,8D2
• InChIKey: NFEZZTICAUWDHU-INFILRCQSA-N
• SMILES: [2H]C1(CC(=C)CC(N1[C@H](C)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O)([2H])[2H])[2H]

Efinaconazole-d4 is a deuterium-labeled version of efinaconazole, an antifungal medication used to treat onychomycosis, a fungal infection of the nails. The deuterium labeling enhances the accuracy of pharmacokinetic studies by allowing precise tracking and quantification of the drug in biological systems through mass spectrometry. This compound is valuable for investigating the metabolism, distribution, and excretion of efinaconazole, optimizing dosing regimens, and understanding its therapeutic efficacy and safety profile in clinical research. Its use supports the development of improved treatment protocols and safety evaluations for antifungal therapies.